Longer US life... but what about Australia?

ASX-listed Neuren Pharmaceuticals has announced patent protection for its flagship product has been extended almost five years to 2041 in the United States, with still no timeline on when the treatment will be available in Australia.

To see the whole article please log in.

James Quintana Pearce

Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.

Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).

You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.

Retype password

Not a member? Sign up here